Background Preclinical studies indicate that the concurrent use of inhibitors of the renin–
angiotensin–aldosterone system (RAAS) may improve outcomes in broad groups of patients …

Background Effect of renin-angiotensin-aldosterone system inhibitors (RAASIs) in
combination with immune checkpoint inhibitors (ICIs) on prognoses in cancer patients …

Background: Immune checkpoint inhibitors (ICIs) are becoming widely used for novel cancer
treatments. Immune-related adverse events, including cardiac toxicity, are frequently …

Background Renin-angiotensin system inhibitors (RASi) have been shown to improve
outcomes in studies of multiple malignancies by effects on the tumor microenvironment to …

Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension
and congestive heart failure. Preclinical data show that ACE plays a role on both innate and …

Whether cardiovascular (CV) disease is associated with clinical outcomes in cancer patients
receiving immunotherapy is unknown. We reviewed the Mayo Clinic database for all cancer …

In the past two decades, treatment outcomes for a wide range of malignancies have
improved remarkably due to the development of novel anti-cancer therapies, including …

Background In patients with genitourinary cancers, the effect of immune checkpoint
inhibitors (ICIs) on kidney function is unknown. Patients and methods This is a retrospective …

Hypertension is the leading risk factor for morbidity and mortality worldwide. However, only
an estimated 20% of those with hypertension achieve adequate blood pressure (BP) control …

Anti-VEGF (vascular endothelial growth factor) agents were associated with increased risk of
several cardiovascular events, while one meta-analysis did not show any significantly …